REGN624.72+0.19%
REGN · US
1y range: 600.66 → 790.81 · as of 2026-07-01
Next earnings
2026-07-30
in 27d
Recent material news
- Regeneron's Applications for gMG Drug Accepted by FDA and EMA2026-06-23T18:24
- REGENXBIO Rises In Premarket As FDA Says No New Studies Needed For NAVSUNLI BLA Resubmission2026-06-22T12:51
- Cemdisiran Regulatory Submissions Accepted for Review by FDA and EMA for the Treatment of Generalized Myasthenia Gravis (gMG)2026-06-22T11:00
- Regeneron Pharmaceuticals Announces That Both The FDA And EMA Have Accepted Regulatory Applications For Cemdisiran To Treat Adult Patients With Generalized Myasthenia Gravis Who Are Anti-Acetylcholine Receptor Antibody-Positive2026-06-22T07:08
- Ocular Therapeutix Maps Regulatory Strategy For Lead Drug Program2026-06-17T10:55
- Regeneron: 'Buy' Revenue Growth And Two Extensive Drug Development Opportunities2026-06-08T02:48
- Regeneron Pharma To Present New Clinical Data And Research From Its Metabolic Disease, Ophthalmology And Rare Disease Pipelines At ADA 86th Scientific Sessions And ENDO 20262026-06-04T07:14
- CytomX Expands Collaboration And Licensing Agreement With Regeneron To Create Conditionally-Activated Bispecific Cancer Therapies Utilizing CytomX's Probody Therapeutic Platform And Regeneron's Veloci-Bi Bispecific Antibody Development Platform2026-06-03T08:04
Want this depth on every stock you watch?
ThickerPeek writes a daily AI digest on 165+ stocks, weekly theses, earnings briefings, and alerts — for €19/mo. Free tier available.
Not investment advice. ThickerPeek is a research tool. AI-written content is informational, not a buy/sell recommendation. Investment decisions are your own responsibility.